SGCB and heart failure: The novel oral sGC stimulator vericiguat sensitizes sGC to nitric oxide by stabilizing nitric oxide binding to the binding site.350 In the VICTORIA trial, vericiguat improved the prognosis of patients with heart failure with reduced ejection fraction.351 The success of the VICTORIA trial builds confidence in the future exploration of novel medications targeting the NO/cGMP pathway.